Toward a Robust System for Biomarker Triage and Validation – EDRN Experience

The Early Detection Research Network (EDRN) has the mission to identify and validate biomarkers for clinical use. The Genitourinary Collaborative Group within EDRN has developed a robust triage and validation system that serves both “facilitator” and “brake” roles. The system consists of the establishment of a reference set of specimens collected under Prospective-specimen-collection-Retrospective-Blinded-Evaluation (PRoBE) design criteria, use of this reference set to pre-validate candidate biomarkers before committing a full-scale validation study, and expansion of this reference set for a full-scale validation study for future biomarkers. This reference set could also be expanded for biomarker discovery purposes.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[3]  H. Klocker,et al.  Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.

[4]  D. McCarthy,et al.  Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.

[5]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[6]  D. Chan,et al.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. , 2007, The Journal of urology.

[7]  J. Witjes,et al.  Molecular PCA3 diagnostics on prostatic fluid , 2007, The Prostate.

[8]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[9]  D. Chan,et al.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.

[10]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[11]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[12]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.